VisiFlora Ingredients: Full 21-Ingredient Formula Breakdown (2026)

This is the ingredient-level companion to our full VisiFlora review. Below, we walk every one of the 21 disclosed ingredients, the clinical evidence behind each, the doses used in published trials, and — the elephant in the room — why only one of the 21 amounts is printed on the label.

1. Quick Answer: What’s Actually in VisiFlora?

According to the label published on the official getvisiflora.com site, one daily VisiFlora capsule delivers a proprietary blend of 21 ingredients: Astaxanthin, Vitamin C, Vitamin E, Copper, Selenium, Chromium, Grape Seed Extract, Rutin, Quercetin, Taurine, Alpha Lipoic Acid, Ginkgo Biloba, Coleus Forskohlii, Eyebright, Vitamin A (as Beta Carotene), Lutein, Zeaxanthin (from Marigold), Zinc (11 mg — the only amount disclosed), Bilberry Extract, Lycopene, and Saffron Extract.

Directions on the label: 1 capsule daily with food.

Read the Full VisiFlora Review →

For pricing, refund process, real-user results, and how VisiFlora stacks up against the full field, jump back to the hub: VisiFlora full review →

2. Eye-Nutrient Formulas: Evidence, Concerns & Trends

Before we dissect VisiFlora specifically, here is the context every eye-supplement shopper should know in 2026:

Where VisiFlora fits. VisiFlora sits in the “broad-spectrum eye botanical” category — a longer ingredient list than any AREDS2 formula, but with the transparency drawback that only zinc has a disclosed amount. This makes ingredient-quality analysis (what we’re doing on this page) more useful than dose-verification analysis.

3. The Full 21-Ingredient Panel

Here is every ingredient on the VisiFlora label, sorted into the 4-pillar framework we’ll use throughout this article. “Best evidence” refers to the strongest published clinical support for that ingredient in eye health specifically.

4. Ingredient-by-Ingredient Deep Dive

Below, one subsection per ingredient. For the AREDS-family core ingredients (lutein, zeaxanthin, zinc, vitamins C & E, copper, beta carotene), we go deeper because that’s where the highest-quality evidence lives.

4.1 Lutein

What it is. A xanthophyll carotenoid concentrated in the macula of the human retina, where it acts as a natural blue-light filter and antioxidant.

Best evidence. The AREDS2 trial (2013, JAMA) established that 10 mg of lutein plus 2 mg of zeaxanthin daily reduced the risk of progression to advanced age-related macular degeneration (AMD) in participants with intermediate AMD, particularly those with low dietary intake of these carotenoids.

Typical clinical dose. 10 mg/day (AREDS2 evidence-based dose). Doses below 6 mg/day are generally considered subtherapeutic for AMD-progression benefit.

Safety notes. Well tolerated; no serious adverse events at study doses. Fat-soluble — take with food (as VisiFlora directs).

4.2 Zeaxanthin (from Marigold)

What it is. The other primary macular xanthophyll; the “from Marigold” designation on VisiFlora’s label suggests it is derived from Tagetes erecta (the standard commercial source), which is the same source used in AREDS2.

Best evidence. AREDS2 — strong. Zeaxanthin sits in the central foveola; lutein predominates in the parafoveal ring. Together they form the yellow macular pigment.

Typical clinical dose. 2 mg/day (AREDS2). Some newer trials use higher isomer-blended doses.

Safety notes. Same profile as lutein — well tolerated; fat-soluble.

4.3 Astaxanthin

What it is. A red-orange carotenoid produced by the microalga Haematococcus pluvialis, unusual among carotenoids for crossing the blood-retina barrier.

Best evidence. Small-to-moderate clinical trials in asthenopia (eye strain from screen use) have shown modest improvements in accommodation and subjective eye fatigue.

Typical clinical dose. 4–12 mg/day in eye-strain trials.

Safety notes. Well tolerated. Some blood-pressure lowering has been observed at higher doses.

4.4 Bilberry Extract

What it is. Vaccinium myrtillus berry extract standardized for anthocyanins — famous for a WWII-era pilots’ night-vision story that modern research has not consistently confirmed.

Best evidence. Mostly traditional-use and observational. Small trials suggest possible modest improvements in eye fatigue.

Typical clinical dose. 80–160 mg standardized extract, twice daily.

Safety notes. Generally safe; theoretical bleeding-risk interaction with anticoagulants at high doses.

4.5 Lycopene

What it is. The red carotenoid abundant in tomatoes; primarily studied for prostate and cardiovascular endpoints, but observational data links higher intake with lower AMD risk.

Best evidence. Observational (cohort studies).

Typical clinical dose. 10–30 mg/day in cardiometabolic trials.

Safety notes. Very safe from dietary or supplemental sources; may temporarily tint skin at extreme intake.

4.6 Vitamin C (Ascorbic Acid)

What it is. Water-soluble antioxidant essential for collagen synthesis (including in the cornea and lens).

Best evidence. Original AREDS formula included 500 mg vitamin C as part of the AMD-progression cocktail — strong.

Typical clinical dose. 500 mg/day (AREDS).

Safety notes. Very safe; doses above 2,000 mg/day may cause GI upset.

4.7 Vitamin E

What it is. A family of fat-soluble antioxidants; alpha-tocopherol is the most active in humans.

Best evidence. AREDS included 400 IU vitamin E — strong.

Typical clinical dose. 400 IU/day (AREDS).

Safety notes. High-dose vitamin E (>400 IU) has been debated for cardiovascular risk; check with your physician if on blood thinners.

4.8 Selenium

What it is. A trace mineral cofactor for the antioxidant enzyme glutathione peroxidase.

Best evidence. Cofactor role in antioxidant defense; no dedicated eye-outcome trials.

Typical clinical dose. 55 mcg RDA; supplemental range 100–200 mcg.

Safety notes. Narrow window — do not exceed 400 mcg/day from all sources.

4.9 Grape Seed Extract

What it is. Polyphenol-rich extract (procyanidins) with systemic antioxidant activity.

Best evidence. Limited direct eye-outcome data; systemic vascular studies more robust.

Typical clinical dose. 100–300 mg/day.

Safety notes. Well tolerated; mild anticoagulant potential.

4.10 Quercetin

What it is. A flavonoid abundant in onions and apples, with anti-inflammatory and antioxidant activity in preclinical models.

Best evidence. Preclinical / mechanistic.

Typical clinical dose. 500–1,000 mg/day (higher than fits a proprietary blend).

Safety notes. Well tolerated; may inhibit certain CYP enzymes.

4.11 Rutin

What it is. A citrus bioflavonoid, quercetin’s glycoside cousin.

Best evidence. Preclinical vascular / capillary-integrity work.

Typical clinical dose. 250–500 mg/day in vascular trials.

Safety notes. Very safe.

4.12 Alpha Lipoic Acid

What it is. A universal antioxidant active in both aqueous and lipid environments; regenerates other antioxidants (vitamin C, E, glutathione).

Best evidence. Preclinical and systemic (diabetic neuropathy is the strongest clinical indication).

Typical clinical dose. 300–600 mg/day.

Safety notes. Generally well tolerated; may lower blood glucose.

4.13 Copper

What it is. An essential trace mineral that must be included whenever zinc is supplemented at higher doses (zinc reduces copper absorption).

Best evidence. AREDS included 2 mg copper specifically to prevent zinc-induced copper deficiency.

Typical clinical dose. 2 mg/day (AREDS).

Safety notes. Very safe at RDA range; important co-ingredient with zinc.

4.14 Ginkgo Biloba

What it is. A widely studied botanical with vasodilatory and antioxidant activity.

Best evidence. Direct eye-outcome studies are limited; most clinical data covers cognitive function and peripheral circulation.

Typical clinical dose. 120–240 mg/day standardized to 24% flavone glycosides.

Safety notes. Bleeding-risk interaction with warfarin, aspirin, NSAIDs — check with physician.

4.15 Coleus Forskohlii

What it is. Contains forskolin, which increases intracellular cAMP; small studies have looked at intraocular pressure (IOP).

Best evidence. Small IOP-focused trials, mostly topical rather than oral.

Typical clinical dose. Highly variable; oral trials have used 250 mg twice daily standardized to 10% forskolin for non-eye endpoints.

Safety notes. May interact with blood pressure medications.

4.16 Taurine

What it is. A conditionally essential amino acid highly concentrated in the retina.

Best evidence. Preclinical — taurine-deficient models show retinal degeneration; human trials at supplemental doses limited.

Typical clinical dose. 500–3,000 mg/day in cardiometabolic trials.

Safety notes. Very safe.

4.17 Chromium

What it is. A trace mineral involved in insulin sensitivity and glucose metabolism.

Best evidence. No strong direct eye-health evidence; included on the basis that stable glucose supports vascular health broadly.

Typical clinical dose. 200–1,000 mcg/day (chromium picolinate).

Safety notes. Generally safe.

4.18 Eyebright (Euphrasia officinalis)

What it is. A traditional European herb long used topically for eye irritation.

Best evidence. Almost entirely traditional-use; no modern clinical AMD data.

Typical clinical dose. Traditional preparations vary widely.

Safety notes. Generally well tolerated orally at supplement doses.

4.19 Vitamin A (as Beta Carotene)

What it is. Beta carotene is a pro-vitamin A carotenoid, converted to retinol as needed.

Best evidence. Original AREDS included 15 mg beta carotene — strong. However, AREDS2 removed beta carotene because it increased lung cancer risk in current and former smokers. This is why AREDS2 formulas replace beta carotene with lutein/zeaxanthin.

Typical clinical dose. Historic AREDS dose: 15 mg (25,000 IU) beta carotene.

Safety notes. Smokers and former smokers should avoid beta carotene supplementation. Discuss with your physician if you fall in this group.

4.20 Saffron Extract

What it is. The dried stigmas of Crocus sativus, standardized for crocin and safranal.

Best evidence. Emerging — small pilot RCTs (Italian and Iranian groups) have shown measurable improvements in retinal flicker sensitivity in early AMD at 20 mg/day.

Typical clinical dose. 20 mg/day standardized extract in the AMD pilot trials.

Safety notes. Well tolerated at 20 mg. Higher doses (grams) can be toxic.

4.21 Zinc — 11 mg (THE ONLY DISCLOSED AMOUNT)

What it is. An essential mineral, cofactor to hundreds of enzymes, and a core AREDS ingredient.

Best evidence. AREDS used 80 mg zinc oxide. AREDS2 later tested a reduced zinc arm at 25 mg and found it non-inferior for many participants (with better tolerability). Both are far above VisiFlora’s 11 mg.

Typical clinical dose. AREDS: 80 mg. AREDS2 low-zinc arm: 25 mg. Adult RDA: 8–11 mg.

Safety notes. 11 mg is the U.S. RDA for adult men — well below the Tolerable Upper Intake Level of 40 mg. Very safe, but factually below AREDS/AREDS2 trial doses.

5. The Dose Problem — Read This Section

This matters because eye-nutrition science is dose-specific. AREDS2 didn’t show a benefit for “some lutein” — it showed a benefit for 10 mg of lutein plus 2 mg of zeaxanthin daily. Halve the dose and you may lose the effect entirely.

Without published amounts, no reader (including us) can verify whether VisiFlora hits the AREDS2 evidence-based targets. Our honest working assumption for any undisclosed-amount ingredient is:

The zinc datapoint tells us something. VisiFlora chose to disclose 11 mg — the adult RDA — which is well below the AREDS 80 mg dose and also below the AREDS2 low-zinc arm at 25 mg. That’s a formulation choice: it prioritizes long-term safety and tolerability (zinc UL is 40 mg) over matching the AREDS trial dose exactly. It is not, factually, an “AREDS2-dosed” zinc.

None of this makes the ingredient panel bad. It makes it unverifiable for dose-based benefit claims. That’s the honest read.

6. The 4-Pillar Framework Explained

To make sense of a 21-ingredient formula, we group the ingredients by biological role:

7. What the Evidence Actually Shows

Let’s be crisp about what eye-nutrient science does and doesn’t claim:

The AREDS/AREDS2 story is real — but narrow.

AREDS and AREDS2 demonstrated that a specific vitamin/mineral cocktail (vitamins C, E, zinc, copper, plus lutein/zeaxanthin in AREDS2) slows progression to advanced AMD in people who already have intermediate AMD. That is a meaningful result. It is not a general “take this and see better” claim for healthy adults, and the AREDS Research Group has been explicit about this.

Lutein + zeaxanthin have solid evidence — at trial doses.

Beyond AREDS2, multiple trials on macular pigment optical density and visual performance support 10 mg lutein + 2 mg zeaxanthin as an evidence-based daily target. This is the one ingredient pairing where dose disclosure matters most.

Saffron has emerging evidence.

Small AMD pilot trials at 20 mg/day are promising but not yet definitive.

Bilberry, eyebright, and several others are traditional-use.

Long history; modern clinical evidence thin. That’s not a knock — it’s just what the literature currently shows.

8. How VisiFlora’s Formula Compares

Read: VisiFlora offers the broadest ingredient list of the three, with the least dose transparency. PreserVision AREDS2 is the exact trial formula, dose-verified, but botanically minimal. Ocuvite is a middle-simplicity option with dose disclosure but lower carotenoid amounts than AREDS2.

9. Who These Ingredients Fit — And Don’t

Best match for VisiFlora’s ingredient profile:

• Adults 40+ wanting broad, botanical-heavy eye-nutrient support
• People who value ingredient breadth (21 items on one cap) over exact-dose verification
• Non-smokers (because of the beta carotene component)
• Anyone who has already had the “which supplement” conversation with their eye doctor and been told broad-spectrum is fine

Skip VisiFlora and choose differently if:

• You need a verified AREDS2 dose (family history of AMD, diagnosed intermediate AMD, ophthalmologist recommendation) — buy PreserVision AREDS2 instead
• You are a current or former smoker — the beta carotene concern applies; discuss with your physician
• You take ginkgo-interacting medications (warfarin, aspirin, other blood thinners, some SSRIs, seizure meds) — talk to your prescriber first
• You need every ingredient amount disclosed for personal-medical or third-party-testing reasons

10. Frequently Asked Questions

How much lutein is in VisiFlora?

The lutein amount is not individually disclosed on the label — it is included within the proprietary blend. Only the total blend weight and the individual zinc amount (11 mg) are listed. Because the AREDS2 evidence-based lutein dose is 10 mg, unverified lutein content is the single biggest evaluation gap for anyone considering VisiFlora primarily for AMD-related benefit.

Does VisiFlora contain the AREDS2 formula?

It contains most of the AREDS2 ingredients (lutein, zeaxanthin, vitamins C & E, zinc, copper) plus 15 additional ingredients — but it does not disclose the amounts of the AREDS2-core ingredients, so it cannot be verified as delivering the AREDS2 doses. If a physician has recommended AREDS2 specifically, choose a product that prints the AREDS2 numbers on the label (such as PreserVision AREDS2).

Why is only zinc disclosed?

Zinc has both a Recommended Dietary Allowance and a Tolerable Upper Intake Level (40 mg), so manufacturers commonly disclose zinc amounts even inside proprietary blends to signal that they stay within safety bounds. VisiFlora’s 11 mg lines up with the adult RDA and sits comfortably below the UL.

Is 11 mg zinc enough?

11 mg equals the adult male RDA and covers baseline nutritional needs. It is not equal to the AREDS trial dose (80 mg) or the AREDS2 low-zinc arm (25 mg). If your goal is nutritional adequacy, 11 mg is fine. If your goal is matching AREDS-trial-level zinc, it is not.

Does VisiFlora have marigold-source zeaxanthin?

Yes — the label specifies “Zeaxanthin (from Marigold),” which is the standard Tagetes erecta-derived commercial source used in AREDS2 and most reputable eye-nutrient formulas.

Where can I see the full Supplement Facts panel?

The full panel — including the proprietary-blend total weight, other ingredients, and any warnings — is published on the official manufacturer site. Read the Full VisiFlora Review →